# Pinshan Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pinshan-biotech

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.pinshanbio.com
- Total disclosed funding: $15M
- Latest round: Series A (Jul 20, 2026)
- Investors on record: 4

## About

Based in Shanghai, China and founded in 2021, Pinshan Biotechnology (Shanghai) Co., Ltd., trading as Pinshan Biotech, operates in the biotechnology sector, specifically targeting the biopharmaceutical industry. In July 2026, Pinshan Biotech raised nearly CNY 100 million in series A funding led by Efung Capital, with participation from FIRHealth Capital, Ruixia Investment and Huzhou Xunshang Venture Capital.

Pinshan Biotech specializes in the research, development, production, and sales of core consumables in the biotechnology and biopharmaceutical sectors. The company’s primary product offerings include essential tools for cell culture, filtration, and chromatographic purification, integral to the manufacturing processes of biopharmaceuticals. Their products enhance the efficiency and reliability of bioprocessing, addressing critical needs in the production of therapeutic agents such as monoclonal antibodies, gene therapies, and cell immunotherapies. 

Pinshan Biotech operates primarily through a B2B transaction model, providing high-quality biotechnology products directly to biopharmaceutical companies. 

The company will use the latest funding for the continued R&D, industrialization capability enhancement, and commercialization promotion of core products such as high-end filtration membrane materials and chromatography packing materials.

## Funding rounds

- Series A, Jul 20, 2026, $15M — Efung Capital, Ruixia Investment, Huzhou Xunshang Venture Capital, FIRHealth Capital

## Investors

- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series A
- Ruixia Investment (https://capitalatlas.ai/funds/ruixia-investment) — Series A
- Huzhou Xunshang Venture Capital — Series A
- FIRHealth Capital (https://capitalatlas.ai/funds/firhealth-capital) — Series A